Laboratory identification of familial thrombophilia: Do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis

Laboratory Hematology

Volumn 11, Issue 3, 2005, Pages 174-184

  Favaloro, Emmanuel J ^a   Soltani, Soma ^a   McDonald, Jane ^a   Grezchnik, Ella ^a   Easton, Leanne ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

ABO blood group; Activated protein C resistance; Age; Antithrombin; Familial thrombophilia; Gender; Laboratory assessment; Normal reference ranges; Protein C; Protein S

Indexed keywords

ANTITHROMBIN; PROTEIN C; PROTEIN S;

AGE; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD GROUP ABO SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENDER; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDICAL AUDIT; PROTEIN ANALYSIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; QUALITY CONTROL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOPHILIA;

ABO BLOOD-GROUP SYSTEM; AGE FACTORS; BLOOD PROTEINS; FALSE POSITIVE REACTIONS; HEMATOLOGIC TESTS; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEX FACTORS; THROMBOPHILIA;

EID: 28044462418     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.05029     Document Type: Article

References (36)

1. Mannucci PM. Laboratory detection of inherited thrombophilia: An historical perspective. Sem Throm Haemost. 2005;31:5-10.
2. Tripodi A. A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. Sem Throm Haemost. 2005;25-32.
3. Favaloro EJ. Diagnostic issues in thrombophilia: A laboratory scientist's view. Sem Throm Haemost. 2005;31:11-16.
4. Hertzberg M. Genetic testing for thrombophilia mutations. Sem Throm Haemost. 2005;31:33-38.
5. Gallus A. Treatment options in thrombophilia. Sem Throm Haemost. 2005;31:118-126.
6. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost. 2003;1:410-411.
7. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost. 2003;1:412-413.
8. Martinelli I. Rebuttal to: Pros and cons of thrombophilia testing: pros. J Thromb Haemost. 2003;1:1311-1312.
9. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemost. 1996;76:824-834.
10. Walker ID, Greaves M, Preston FE, on behalf of the Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology, Guideline: Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512-528.
11. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis: Venous thromboembolism, myocardial infarction, stroke, and other conditions. Arch Pathol Lab Med. 2002;126:1281-1295.
12. De Stefan V, Ross E, Paciaron K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87:1095-1108.
13. Favaloro EJ, Mirochnik O, McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT- based assays. Br J Biomed Sci. 1999;56:23-33.
14. Favaloro EJ, Orsag I, Bukuya M, McDonald D. A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology. 2002;34:348-355.
15. Favaloro EJ, Bonar B, Sioufi J, et al. (on behalf of the RCPA QAP in Haematology). Multi-laboratory testing of thrombophilia: current and past practice in Australasia as assessed through the RCPA Haematology QAP. Sem Throm Haemost. 2005;31:49-58.
16. Hertzberg M, Neville S, Favaloro EJ, MacDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol. 2005,123:189-193.
17. O'Donnell JO, Laffan MA. The relationship between ABO histoblood group, factor VIII and von Willebrand factor. Transfusion Med. 2001;11:343-351.
18. Shima M, Fujimura Y, Nishiyama T, et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang. 1995;68:236-240.
19. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol. 2000; 108:259-264.
20. Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol. 1994;86:798-803.
21. Mirochnik O, Halim-Kertanegar N, Henniker AJ, et al. A null factor V null mutation at Arg 506 causes a false positive factor V Leiden result. Thromb Haemost. 1999;82:1198-1199.
22. Rodeghiero F, Tosetto A. The VITA project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen - relationship with physiological variables and establishment of reference ranges. Thromb Haemost. 1996;76:226-233.
23. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the atherosclerosis risk in communities (ARIC) study. Thromb Haemost. 1993;70:762-767.
24. Tait RC, Walker ID, Islam SI, et al. Protein C activity in healthy volunteers - influence of age, sex, smoking and oral contraceptives. Thromb Haemost, 1993;70:281-285.
25. Favaloro EJ, Mehrabani PA, Koutts J. Laboratory assessment of von Willebrand factor: altered interpretation of laboratory data, and altered diagnosis of von Willebrand's disease, as influenced by the use of different vWF assays and assay conditions. Clin Appl Thromb/Hemost. 1997;3:110-118.
26. Meijer P, Haverkate F. External quality assessment and the laboratory diagnosis of thrombophilia. Sem Throm Haemost. 2005;31:59-65.
27. Jennings I, Kitchen S, Woods TAL, Preston FE. Multi-laboratory testing in thrombophilia through the UK NEQAS (blood coagulation) quality assurance programme. Sem Thromb Haemost. 2005;31:66-72.
28. Favaloro EJ. Learning from the peer-assessment external quality assurance multi-laboratory thrombophilia test process. Sem Thromb Haemost. 2005;31:85-89.
29. Henkens CM, Bom VJ, Van der Schaaf W, et al. Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Thromb Haemost. 1995;74:1271-1275.
30. Sakkinen PA, Cushman M, Psaty BM, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost. 1998;80:134-139.
31. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001;113:636-641.
32. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-784.
33. Florell SR, Rodgers GM. Utilization of testing for activated protein C resistance in a reference laboratory. Am J Clin Path. 1996; 106:248-252.
34. Allman-Farinelli M, Dawson B. Diet and aging: Bearing on thrombosis and haemostasis. Sem Thromb Haemost. 2005;31:111-117.
35. Liberti G, Bertina RM, Rosendaal FR. Hormonal state rather than age influences cut-off values of protein S: re-evaluation of the thrombotic risk associated with protein S deficiency. Thromb Haemost. 1999;82:1093-1096.
36. Hoffman R, Brenner B. Thrombophilia related issues in women and children. Sem Thromb Haemost. 2005;31:97-103.